WS #10943
BridgeBio announces positive Phase 3 results for infigratinib in achondroplasia, plans NDA submission in Q3 2026.
BridgeBio Positive Trial Results
BridgeBio announces positive Phase 3 results for infigratinib in achondroplasia, plans NDA submission in Q3 2026.